白介素6与恶性肿瘤的相关性研究(3)
[8] Yi Tang，Krit Kitisin，Wilma Jogunoori，etaL. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-βand IL-6 signaling. PNAS. 2008；105 (7 )2445–2450.
[9] Maurizio Soresi，Lydia Giannitrapani，Fabio D’Antona. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol.2006；12(16):2563-2568.
[10] C. Porta，M. De Amici，S. Quaglini. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Annals of Oncology. 2008；19: 353–358.
[11] Castro FA, Haimila K, Sareneva I， etal. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int J Cancer. 2009；125(8):1851-8.
[12] Veerapaneni P, Kirma N, Nair HB, etal Elevated aromatase expression correlates with cervical carcinoma progression. Gynecol Oncol. 2009；114(3):496-500.
[13] Kotowicz B, Fuksiewicz M, Kowalska M，etal. The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients. Int J Gynecol Cancer.2008；18(6):1279-84.
[14] Rusiecka M，Sedlaczek P， Rusiecki L，etal. The value of the cytocins and the solubility of theirs receptors in the serum of the patients with the cervical cancer .Ginekol Pol.2007；78(9):691-5.
[15] Nari?a D, Seclaman E, Ursoniu S, etal. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Rom J Morphol Embryol. 2011;52(4):1261-7.
[16] Reynaud D, Pietras E, Barry-Holson K, etal. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell.2011；20(5):661-73.
廣东省中医药局建设中医药强省科研课题(2010443，20121274)，广东省医学科研基金资助(A2012481), 百拇医药(赵昌林 韩宇健 赵延军 李丽君 王珍)
[9] Maurizio Soresi，Lydia Giannitrapani，Fabio D’Antona. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol.2006；12(16):2563-2568.
[10] C. Porta，M. De Amici，S. Quaglini. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Annals of Oncology. 2008；19: 353–358.
[11] Castro FA, Haimila K, Sareneva I， etal. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int J Cancer. 2009；125(8):1851-8.
[12] Veerapaneni P, Kirma N, Nair HB, etal Elevated aromatase expression correlates with cervical carcinoma progression. Gynecol Oncol. 2009；114(3):496-500.
[13] Kotowicz B, Fuksiewicz M, Kowalska M，etal. The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients. Int J Gynecol Cancer.2008；18(6):1279-84.
[14] Rusiecka M，Sedlaczek P， Rusiecki L，etal. The value of the cytocins and the solubility of theirs receptors in the serum of the patients with the cervical cancer .Ginekol Pol.2007；78(9):691-5.
[15] Nari?a D, Seclaman E, Ursoniu S, etal. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Rom J Morphol Embryol. 2011;52(4):1261-7.
[16] Reynaud D, Pietras E, Barry-Holson K, etal. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell.2011；20(5):661-73.
廣东省中医药局建设中医药强省科研课题(2010443，20121274)，广东省医学科研基金资助(A2012481), 百拇医药(赵昌林 韩宇健 赵延军 李丽君 王珍)